ALX Oncology Holdings Inc. ALXO
Regular-session close
After hours · Nov 17, 4:00 PM ET
- YTD
- -11.06%
- 1 year
- -35.58%
- Market cap
- 138.97M
- EPS (ttm)
- -0.87
- Shares out
- 52.74M
- Forward P/E
- -0.68
- YTD return
- -11.06%
- 1-year return
- -35.58%
- 50-day average
- 1.50
- 200-day average
- 6.33
- Enterprise value
- -45.77M
- Volume
- 437.98K
- Avg volume
- 1.16M
- Open
- 0.99
- Previous close
- 1.00
- Day's range
- 0.96 – 1.04
- 52-week range
- 0.862 – 2.66
- Beta
- 1.04
- Analysts
- Buy
- Price target
- 7.67 (+662.9%)
Key statistics
- Price / book
- 0.71
- Free cash flow
- -74.55M
- Total cash
- 148.57M
- Total debt
- 17.36M
- Return on equity
- -98.94%
- Short % of float
- 23.56%
Fundamental scorecard
5 of 25 checks passed on ALXO’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.78 | -0.58 | +0.20 | +25.64% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | -0.76 | +0.01 | +1.30% |
| Aug 8, 2024 | Jun 1, 2024 | -0.77 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.87 | -0.71 | +0.16 | +18.39% |
| May 9, 2024 | Mar 1, 2024 | -0.87 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.84 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Jefferies | down | Buy | Hold |
| Dec 18, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 12, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 16, 2024 | UBS | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- alxoncology.com
News
ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript ALX Oncology Holdings Q3 Adj. EPS $(0.13) Beats $(0.14) Estimate
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on ALXO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GARCIA PETER S | Chief Financial Officer | Purchase | Jun 12, 2024 | 122,348 |
| HEMRAJANI REKHA | Director | Purchase | Dec 1, 2024 | 33,000 |
| LETTMANN JASON | Chief Executive Officer | Purchase | Mar 13, 2024 | 171,620 |
| PINTO SHELLY | Officer | Sale | Aug 13, 2024 | 91,549 |
| PONS JAUME | President | Sale | Aug 13, 2024 | 591,510 |
| RANDOLPH SOPHIA | Officer | Sale | Aug 13, 2024 | 325,711 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| venBio Partners LLC | 18.39% | 9,699,925 | 17.75M | Sep 29, 2024 |
| FMR, LLC | 11.12% | 5,865,106 | 10.73M | Sep 29, 2024 |
| Tang Capital Management, LLC | 7.97% | 4,204,735 | 7.69M | Sep 29, 2024 |
| Vivo Capital, LLC | 7.65% | 4,034,522 | 7.38M | Sep 29, 2024 |
| Redmile Group, LLC | 7.27% | 3,836,576 | 7.02M | Sep 29, 2024 |
| Blackrock Inc. | 4.93% | 2,601,776 | 4.76M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 3.20% | 1,689,620 | 3.09M | Aug 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 2.00% | 1,057,220 | 1.93M | Aug 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.87% | 984,586 | 1.80M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.64% | 867,199 | 1.59M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.58% | 835,504 | 1.53M | Oct 30, 2024 |
| Fidelity Small Cap Growth K6 Fund | 1.18% | 621,497 | 1.14M | Aug 30, 2024 |
